Pricing Log in Create free account
Saturday 17 October 2026 Export SIGA’s income statement to Excel — free account

Siga Technologies Inc.

SIGA Healthcare Drug Manufacturers Specialty & Generic

Siga Technologies Inc.’s revenue for fiscal 2025 (year ended December 2025) was $94.6 million, down 31.8% from fiscal 2024. In the quarter to June 2026, revenue fell 49.5%, EPS fell 66.0% and free cash flow fell 76.0%, each against the same quarter a year earlier. Dividend growth for five consecutive years.

3.17 0.02 −0.63%
Market cap
$229.2M
P/E
0.0×
Fwd P/E
28.7×
Dividend yield
0.00%
F-score
5/9
Altman Z
14.28
Beneish M
−4.02
Dividend safety
36/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 42.68%

Capital & Financial Ratios $m

Market Cap 229.20
Revenue 53.66
Net Income (2.79)
Free Cash Flow (20.17)
Net Debt (117.58)
Current Ratio 21.72 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E 28.70
P/S ratio 4.24
P/B ratio 1.38
Past 5Y EPS Growth (14.73%) (below 0%: weak)
This Y EPS Growth (18.29%) (below 0%: weak)
Next Y EPS Growth 153.73% (at or above 15%: strong)
Next Y revenue growth (36.71%) (below 0%: weak)
Next 5Y EPS Growth 1.00%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 5.0×, against a ten-year median of 4.9×; over the ten years it ranged from −10.4× in 2016 to 97.7× in 2018.
P/S against its own 10 years 47.14%
10-year low 10-year high
P/B against its own 10 years 1.78%
10-year low 10-year high
EV/Sales against its own 10 years 51.14%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate 0.00
Annual Dividend Yield 0.00%
total individual payouts
2027 Powerpack
2026 0.60
0.60
2025 0.60
0.60
2023 0.00
0.45
2022 0.00
0.45
2021 Powerpack
2020 Powerpack
2019 Powerpack
2018 Powerpack
2017 Powerpack
2016 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 150 155 155 118
Receivables 21 21 3 7
Inventory 64 50 49 41
Other — — — —
239 231 213 170
2023 2024 2025 Q'26
Payables 1 1 1 1
ST’ Debt — — — —
Other — — — —
54 25 18 8

Compound Annual Growth %

10y 5y 3y
Sales 27.74% (5.42%) (5.13%)
Cash Flow 14.62% (9.48%) 1.47%
Earnings 0.00% (16.20%) (11.78%)
Book Value 0.00% 8.90% 5.33%

Revenue $m

Mar Jun Sep Dec Year
’26 6 41 — — —
’25 7 81 3 4 95
’24 25 22 10 81 139
’23 8 6 9 116 140
’22 11 17 72 11 111
’21 5 9 5 115 134
’20 3 40 44 38 125
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (9) 15 — — —
’25 7 63 (10) (17) 43
’24 (6) 6 (7) 56 49
’23 24 (4) (5) 79 95
’22 57 (2) (5) (8) 42
’21 (5) (1) 2 16 11
’20 3 (9) 31 46 72
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (9) 15 — — —
’25 7 63 (10) (17) 43
’24 (6) 6 (7) 56 49
’23 24 (4) (5) 79 95
’22 57 (2) (5) (8) 42
’21 (5) (1) 2 16 11
’20 3 (9) 31 46 72
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.05) 0.17 — — —
’25 (0.01) 0.49 (0.09) (0.08) 0.32
’24 0.14 0.03 0.02 0.63 0.82
’23 (0.01) (0.04) (0.01) 1.01 0.95
’22 0.00 0.03 0.45 (0.01) 0.46
’21 (0.01) 0.00 (0.04) 0.98 0.91
’20 (0.11) 0.26 0.31 0.26 0.71
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 0.35 2.80 4.21 4.28 3.96 5.66 5.84 4.22 4.26 4.95

Analyst estimates 2026–2028

Powerpack
High 3.35 5.24 8.47 8.09 8.10 9.82 26.99 8.49 12.83 9.62
People
People Employees 36 37 41 41 42 39 39 45 46 49
Revenue/emp, $m 0.42 0.33 11.64 0.65 2.98 3.43 2.84 3.11 3.02 1.93
Income, $m
Income, $m Revenue 15 12 477 27 125 134 111 140 139 95
Gross margin, % 100.00 100.00 80.03 93.33 88.16 87.58 90.58 87.26 77.44 68.59
EBT (40) (38) 412 (10) 74 89 44 88 76 30
EBT margin, % (264.78) (312.41) 86.29 (38.06) 58.83 66.81 39.84 62.73 54.84 32.12
Net income (40) (36) 422 (7) 56 69 34 68 59 23
Depreciation 0 0 0 1 1 1 1 1 1 1
Per share, $
Per share, $ Revenue 0.26 0.16 5.97 0.33 1.58 1.77 1.52 1.96 1.95 1.32
Earnings (0.69) (0.46) 5.28 (0.09) 0.71 0.92 0.46 0.95 0.83 0.33
Cash flow (2.04) (0.23) 0.86 (0.22) 0.90 0.15 0.57 1.33 0.68 0.61
Capex 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Free cash flow (2.04) (0.23) 0.86 (0.22) 0.90 0.15 0.57 1.33 0.68 0.60
Book value (5.03) (4.10) 1.29 1.21 1.64 2.31 2.33 2.76 3.03 2.78
Shares, m 57 79 80 81 79 75 73 71 71 72
Valuation, ×
Valuation, × P/E 0.00 0.00 1.50 0.00 10.10 8.07 15.12 6.10 7.33 18.28
P/S 11.18 30.86 1.32 14.45 4.61 4.24 4.63 2.97 3.09 4.62
P/B 0.00 0.00 6.14 3.95 4.44 3.25 3.01 2.11 1.98 2.20
EV/Sales 13.16 34.32 1.25 14.38 4.94 4.66 5.17 3.03 3.11 4.66
EV/FCF (1.69) (22.76) 8.68 (21.09) 8.63 54.37 13.78 4.48 8.86 10.23
Cash, $m
Cash, $m Operating cash flow (117) (18) 69 (18) 72 11 42 95 49 43
Capex 0 0 0 0 0 0 — 0 0 0
Free cash flow (117) (18) 69 (18) 72 11 42 95 49 43
Balance, $m
Balance, $m Working capital 62 31 110 88 133 178 164 185 206 195
Total debt 67 71 76 80 2 3 2 — — —
Net debt 28 40 (37) (81) (118) (103) (99) (150) (155) (155)
Shareholders’ equity (287) (323) 103 98 130 174 170 197 216 199
Returns, %
Returns, % ROA (22.90) (23.71) 242.34 (3.60) 32.34 38.10 16.55 30.29 23.75 10.04
ROIC 0.00 0.00 334.46 (8.62) 443.69 78.23 37.39 111.88 72.41 33.78
ROE 13.88 11.87 (383.07) (7.22) 49.51 45.68 19.68 37.09 28.70 11.23
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Siga Technologies Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CGC Canopy Growth Corporation $311.2M — (loss-making) — (loss-making) +12.41% (above 0%: growing) n/m −117.60% (below 0%: shrinking) 27.40% (27.24%) Compare
ANIK Anika Therapeutics Inc. $276.9M — (loss-making) — (loss-making) +15.56% (above 0%: growing) n/m +61.58% (above 0%: growing) 65.15% 9.06% Compare
ACB Aurora Cannabis Inc. $265.8M — (loss-making) — (loss-making) −31.15% (below 0%: shrinking) n/m −293.56% (below 0%: shrinking) 52.73% (12.92%) Compare
BIOA BioAge Labs, Inc. $245.6M — (loss-making) — (loss-making) +1.62% (above 0%: growing) n/m +2.68% (above 0%: growing) 100.00% (1,196.78%) Compare
LFCR Lifecore Biomedical, Inc. $244.1M — (loss-making) — (loss-making) −6.25% (below 0%: shrinking) n/m −117.03% (below 0%: shrinking) 35.34% 7.51% Compare
SIGA Siga Technologies Inc. $229.2M — (loss-making) 28.7× −49.45% (below 0%: shrinking) −66.00% (below 0%: shrinking) −75.95% (below 0%: shrinking) 57.17% 33.91%
AKBA Akebia Therapeutics, Inc. $192.7M — (loss-making) — (loss-making) −21.36% (below 0%: shrinking) n/m −88.99% (below 0%: shrinking) 78.78% (12.88%) Compare
DERM Journey Medical Corporation $144.7M — (loss-making) 91.8× +23.33% (above 0%: growing) n/m −84.08% (below 0%: shrinking) 66.81% 2.46% Compare
ORGO Organogenesis $142.8M — (loss-making) — (loss-making) −56.68% (below 0%: shrinking) n/m +10.29% (above 0%: growing) 45.90% (116.54%) Compare
Median of peers $244.8M — — −2.31% — −86.54% 58.94% (12.90%)

All 86 Drug Manufacturers Specialty & Generic stocks →

Siga Technologies Inc. (SIGA) key facts

  • Concern: Siga Technologies Inc.’s revenue for fiscal 2025 (year ended December 2025) was $94.6 million, down 31.8% from fiscal 2024.
  • Siga Technologies Inc. (SIGA) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, SIGA traded at $3.17, a market capitalization of $229.2 million.
  • Return on equity was 11.2% and debt-to-equity 0.00.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 14.28 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Siga Technologies Inc. (SIGA) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/SIGA · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com